Lunai Bioworks (NASDAQ:LNAI) Releases Earnings Results

Lunai Bioworks (NASDAQ:LNAI) posted its quarterly earnings data on Friday. The company reported $0.13 EPS for the quarter, Zacks reports.

Lunai Bioworks Trading Up 2.9%

Shares of Lunai Bioworks stock traded up $0.03 on Friday, reaching $1.06. The stock had a trading volume of 593,767 shares, compared to its average volume of 8,996,835. Lunai Bioworks has a 1 year low of $0.81 and a 1 year high of $21.00. The company has a market cap of $24.57 million, a price-to-earnings ratio of -0.14 and a beta of 0.31.

Wall Street Analysts Forecast Growth

LNAI has been the subject of a number of research reports. Wall Street Zen lowered shares of Lunai Bioworks to a “strong sell” rating in a research report on Friday, October 3rd. Weiss Ratings assumed coverage on shares of Lunai Bioworks in a research note on Wednesday, October 8th. They set a “sell (e+)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase.